echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > From a net profit of 200 million to a net loss of 500 million, will new crown vaccine manufacturers make money this year?

    From a net profit of 200 million to a net loss of 500 million, will new crown vaccine manufacturers make money this year?

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    New crown vaccine manufacturers are losing money earlier than the market expected


    On August 8, 2022, the US biotechnology company Novavax (NVAX) released its semi-annual report showing that the company lost money in the first half of the year


    The company's recombinant protein new crown vaccine, which received emergency use authorization in Indonesia in November 2021, did not start to be used in the United States until July this year.


    "We now don't expect to have any new revenue from the U.


    Novavax was profitable in the first quarter of this year


    Novavax was profitable in the first quarter of this year


    Investors did not buy it.


    From profit to loss, the transition is too fast

    From profit to loss, the transition is too fast

    The companies holding the new crown vaccine have been very hot in the past two years.


    The company is the fourth new coronavirus vaccine authorized for use in the United States after Pfizer in the United States, BioNTech in Germany, Moderna in the United States, and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson


    Increases in selling and administrative expenses dragged Novavax down from $140 million in the year-ago period to $200 million this year, mainly due to higher professional expenses for the COVID-19 vaccine program


    Increases in selling and administrative expenses dragged Novavax down from $140 million in the year-ago period to $200 million this year, mainly due to higher professional expenses for the COVID-19 vaccine program


    The company believes that the loss of $510 million in the second quarter was due to the decrease in revenue under the above-mentioned U.


    Novavax sold 3 million doses of the vaccine in the second quarter, recording $55 million in sales, compared with $586 million in the first quarter


    The company spent $289.


    The new crown vaccine developed by Novavax is considered by the industry to have fallen behind competitors and failed to achieve the expected effect, which is one of the reasons why the company has cut its revenue forecast for 2022


    The U.


    Novavax executives have also predicted that recombinant protein vaccines may appeal to those who are hesitant to use newer technology vaccines
    .
    However, from the perspective of sales, there are already three vaccines ahead, and the demand for new vaccines is not obvious
    .

    Novavax executives have also predicted that recombinant protein vaccines may appeal to those who are hesitant to use newer technology vaccines
    .
    However, from the perspective of sales, there are already three vaccines ahead, and the demand for new vaccines is not obvious
    .

    At present, Novavax has slashed its full-year revenue forecast by about 50%
    .

    Vaccines are hot and cold all over the world, and manufacturers’ desire to survive has greatly increased

    Vaccines are hot and cold all over the world, and manufacturers’ desire to survive has greatly increased

    Another new crown vaccine manufacturer that has made a big splash in 2021, the German biological company Baintech, also experienced a decline in revenue in the second quarter
    .

    In the second quarter of 2022, the company's revenue was 3.
    2 billion euros, down from 5.
    31 billion euros in the same period last year
    .

    Byrne Tech believes that the dynamics of the new crown pandemic are still fluctuating, resulting in a phased pattern of orders for the new crown vaccine, resulting in fluctuations in revenue from quarter to quarter
    .
    This quarter-to-quarter volatility in revenue the company expects to persist through the current year
    .

    The dynamics of the Covid-19 pandemic are still in flux, resulting in a phased pattern of orders for Covid-19 vaccines, resulting in volatility in revenue from quarter to quarter
    .
    This quarter-to-quarter volatility in revenue the company expects to persist through the current year
    .

    At the same time, the company's second-quarter net profit also fell, from 2.
    79 billion euros last year to 1.
    67 billion euros this year
    .

    Byrne Tech expects to start deliveries of the two vaccines against Omicron as early as October 2022, which will help stimulate demand in the fourth quarter
    .
    BioNTech and Pfizer had already submitted data for a new crown vaccine against Omicron BA.
    1 to the European Medicines Agency in July, with delivery still pending approval
    .
    The other, a vaccine recommended by the U.
    S.
    drug regulator for the BA.
    4 and BA.
    5 subtypes of Omicron, will begin clinical trials this month, with initial doses expected to be delivered in October
    .

    The company reiterated its 2022 vaccine revenue forecast of 13 billion to 17 billion euros, down from 19 billion euros last year
    .
    The confidence comes from the company's expectation that after the launch of the Omicron vaccine, many countries may promote vaccination as a booster shot to help the company's revenue return to growth, so it maintains this year's new crown vaccine revenue forecast at 13 billion to 17 billion euros unchanged, But related revenue is still below last year's 19 billion euros
    .

    The market's evaluation of Biontech is still good.
    The company has a lot of products under development.
    Currently, there are 18 candidate products in the field of oncology and 23 clinical trials are underway
    .

    The market's evaluation of Biontech is still good.
    The company has a lot of products under development.
    Currently, there are 18 candidate products in the field of oncology and 23 clinical trials are underway
    .

    Novavax is also developing Omicron BA.
    1 specific vaccine, Omicron BA.
    5 specific vaccine and so on
    .
    The company is focusing on bringing the new crown vaccine to the market with the new crown vaccine as its main product.
    To this end, it is still collecting data to improve the performance of the vaccine, and research in the minor group is being carried out
    .
    The company is also working on a flu vaccine
    .

    For vaccine manufacturers with few products on the market, the mutation of the new coronavirus is one of the risk factors
    .
    The data calculated by the researchers based on the emergence of new mutants of the new coronavirus is that there will be two new coronavirus mutations every month in the world
    .
    According to incomplete statistics from Caijing·Great Health, as of August 8, four Omicron mutant virus clades (BA.
    1, BA.
    2, BA.
    4 and BA.
    5) have been discovered in China.
    ) of 15 subclades of input virus strains
    .

    For vaccine manufacturers with few products on the market, the mutation of the new coronavirus is one of the risk factors
    .

    Novavax admitted in the semi-annual report that the emergence and spread of new coronavirus variants may affect the market acceptance or sales of existing new crown vaccines.
    The company's strategy of developing new versions of vaccines to deal with certain variants also may not be successful
    .

    CITIC Securities predicts that China's potential market space for strengthening needles in the future still has a scale of 6 billion to 10 billion yuan
    .
    The brokerage analysis believes that there is still a huge demand for strengthening immunity.
    Compared with homologous strengthening, sequential strengthening has a more effective protective effect.
    In the future, there is an urgent need for vaccines against Omicron variant strains, which are developed with BA.
    2 as the strain.
    The Omicron variant vaccine may provide better protection
    .

    The pace of Covid-19 vaccines has slowed, and Chinese companies are not immune
    .
    On July 24, Kangtai Bio (300601.
    SZ) said that since the second quarter, the domestic and international new crown vaccination environment has undergone major changes, the demand for new crown vaccines has declined rapidly, and the company's new crown vaccine sales have declined rapidly
    .

    The pace of Covid-19 vaccines has slowed, and Chinese companies are not immune
    .

    An investor who has invested in a new crown vaccine company told Caijing and Great Health that he no longer pays attention to the new crown vaccine project
    .

    Some Chinese vaccine companies predict that the new crown vaccine will maintain an upward trend in 2022, but it will be more difficult to advance vaccination in the future, and the growth rate of the global vaccination rate will gradually slow down
    .

    Some Chinese vaccine companies predict that the new crown vaccine will maintain an upward trend in 2022, but it will be more difficult to advance vaccination in the future, and the growth rate of the global vaccination rate will gradually slow down
    .

    In order to ensure that "no one household or one person is missed", many places have launched "door-to-door seedling delivery" services to increase people's willingness to be vaccinated
    .
    On August 10, Jiading District, Shanghai sent additional mobile vaccination teams into communities and villages to carry out vaccination work to facilitate the vaccination of the elderly against the new crown
    .

    In Yuhua District, Changsha City, the joint staff of the community health service centers and community doctors jointly formed a mobile vaccination team to carry out mobile vaccination work for the elderly over 60 years old in the community, providing "miao" to the door for the elderly with limited mobility
    .
    After the vaccination, the medical staff accompanied and observed for 30 minutes.
    In response to possible adverse reactions, doctors stationed at the site to treat them in time
    .

    Baodi District, Tianjin recently emphasized that it is necessary to fully integrate grid personnel, sinking cadres, community volunteers and other forces, make full use of experience and practices such as "knock on the door", and accurately map out the inoculation targets
    .

    In China, more than 1.
    3 billion people have been vaccinated against the new crown
    .
    As of August 9, 239 million people over the age of 60 had been vaccinated across the country, and 226 million had been vaccinated throughout the entire course, accounting for 90.
    44% and 85.
    63% of the elderly population, respectively
    .

    As of August 9, 239 million people over the age of 60 had been vaccinated across the country, and 226 million had been vaccinated throughout the entire course, accounting for 90.
    44% and 85.
    63% of the elderly population, respectively
    .

    The global inoculation of the new crown vaccine is gradually saturated
    .
    As of August 9, the data statistics platform Our World in Data shows that 67.
    2% of the world's population has received at least one dose of the new crown vaccine
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.